Target Name: RNF186
NCBI ID: G54546
Review Report on RNF186 Target / Biomarker Content of Review Report on RNF186 Target / Biomarker
RNF186
Other Name(s): FLJ20225 | ring finger protein 186 | E3 ubiquitin-protein ligase RNF186 | Ring finger protein 186 | RP11-91K11.1 | RN186_HUMAN | RING finger protein 186

RNF186: A Drug Target / Disease Biomarker

RNA-Fucosin (RNF186) is a drug target and a biomarker that is derived from the RNA-protein complex found in the endoplasmic reticulum (ER). It is a 22 kDa protein that is composed of a 19 kDa alpha-helices and a 3 kDa beta-sheet. RNA-Fucosin plays a crucial role in the regulation of various cellular processes including cell adhesion, migration, and invasion.

The RNA-Fucosin gene was first identified in the human genome in 2008 and has since been shown to be expressed in various tissues and organs, including brain, heart, liver, and pancreas. The gene has been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion, and has been implicated in the development and progression of various diseases, including cancer.

One of the unique features of RNA-Fucosin is its ability to interact with other proteins in the endoplasmic reticulum, including the protein known as Retinoblastoma gene (RB) 1. This interaction between RNA-Fucosin and RB1 has been shown to play a role in the regulation of cellular processes such as protein folding and localization.

In addition to its role in cellular processes, RNA-Fucosin has also been shown to be involved in the regulation of various signaling pathways, including the TGF-beta pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of various diseases, including cancer.

The RNA-Fucosin gene has also been shown to be involved in the regulation of the cell cycle, specifically in the G1 phase of the cell cycle. This is important for the regulation of cell growth and the maintenance of cellular stability, and is a key factor in the development and progression of various diseases, including cancer.

In conclusion, RNA-Fucosin is a drug target and biomarker that has been shown to play a crucial role in the regulation of various cellular processes, including cell adhesion, migration, and invasion, as well as the regulation of cellular signaling pathways and the cell cycle. Further research is needed to fully understand the role of RNA-Fucosin in the development and progression of various diseases.

Protein Name: Ring Finger Protein 186

Functions: E3 ubiquitin protein ligase that is part of an apoptotic signaling pathway activated by endoplasmic reticulum stress (PubMed:23896122). Stimulates the expression of proteins specific of the unfolded protein response (UPR), ubiquitinates BNIP1 and regulates its localization to the mitochondrion and induces calcium release from the endoplasmic reticulum that ultimately leads to cell apoptosis (PubMed:23896122). Plays a role in the maintenance of intestinal homeostasis and clearance of enteric pathogens. Upon NOD2 stimulation, ubiquitinates the ER stress sensor activating transcription factor 6/ATF6 and promotes the unfolded protein response UPR (PubMed:34623328). Participates in basal level of autophagy maintenance by regulating the ubiquitination of EPHB2 and EPHB3. Upon stimulation by ligand EFNB1, ubiquitinates EPHB2 and further recruits MAP1LC3B for autophagy induction (PubMed:33280498). Controls nutrient sensing by ubiquitinating Sestrin-2/SESN2, which is an intracellular sensor of cytosolic leucine and inhibitor of mTORC1 activity (PubMed:31586034)

The "RNF186 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF186 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P | RNU4-53P | RNU4-62P | RNU4-6P